Indivior (NASDAQ:INDV) Issues Earnings Results

Indivior (NASDAQ:INDV) issued its quarterly earnings results on Monday. The company reported $5.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $4.86, FiscalAI reports. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $343.00 million for the quarter, compared to analyst estimates of $307.55 million.

Indivior Stock Performance

INDV opened at $40.01 on Monday. Indivior has a twelve month low of $19.31 and a twelve month high of $42.81. The firm has a market cap of $4.88 billion, a price-to-earnings ratio of 20.52 and a beta of 0.86. The company has a fifty day simple moving average of $39.18 and a 200 day simple moving average of $35.49.

Insiders Place Their Bets

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the transaction, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. This represents a 11.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the transaction, the insider directly owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of hedge funds have recently bought and sold shares of INDV. Raymond James Financial Inc. purchased a new stake in Indivior during the 2nd quarter worth approximately $26,000. Quarry LP acquired a new stake in shares of Indivior during the 3rd quarter valued at approximately $26,000. Aquatic Capital Management LLC acquired a new position in shares of Indivior in the 3rd quarter valued at about $104,000. California State Teachers Retirement System acquired a new position in Indivior in the second quarter valued at approximately $112,000. Finally, Tower Research Capital LLC TRC grew its stake in Indivior by 851.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,567 shares of the company’s stock worth $156,000 after buying an additional 9,456 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on INDV shares. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 24th. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Finally, Barclays began coverage on Indivior in a research note on Thursday, June 18th. They issued an “overweight” rating and a $46.00 target price for the company. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Indivior has an average rating of “Moderate Buy” and a consensus target price of $43.67.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.